Advanced Solid Tumor Clinical Trials in Houston, Texas

54 studies are recruiting for advanced solid tumor in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

   A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   21 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT06859762 on ClinicalTrials.gov

3. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

4. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

5. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

   This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas - MD Anderson Cancer Center, Houston, Texas

   Locations

   18 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT05898399 on ClinicalTrials.gov

6. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   28 in total

   Run by

   BeOne Medicines

   See if you can join NCT05981703 on ClinicalTrials.gov

7. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   101 in total

   Run by

   BeOne Medicines

   See if you can join NCT06589596 on ClinicalTrials.gov

8. A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

   This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   14 in total

   Run by

   BeOne Medicines

   See if you can join NCT07181681 on ClinicalTrials.gov

9. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

   This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   62 in total

   Run by

   BeOne Medicines

   See if you can join NCT06120283 on ClinicalTrials.gov

10. Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in parti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    34 in total

    Run by

    BeOne Medicines

    See if you can join NCT06598800 on ClinicalTrials.gov

11. A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

    The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    22 in total

    Run by

    BeOne Medicines

    See if you can join NCT07226349 on ClinicalTrials.gov

12. ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

    Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    14 in total

    Run by

    Adcendo ApS

    See if you can join NCT06597721 on ClinicalTrials.gov

13. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    33 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06561685 on ClinicalTrials.gov

14. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    11 in total

    Run by

    EMD Serono Research & Development Institute, Inc.

    See if you can join NCT06641908 on ClinicalTrials.gov

15. Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

    ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    3 in total

    Run by

    OncoC4, Inc.

    See if you can join NCT07408258 on ClinicalTrials.gov

16. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    39 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

17. A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

    The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours. Advanced solid tumours are cancers that can occur in various organs or tissues and have spread from their original site to nearby tissues or oth…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    10 in total

    Run by

    Ipsen

    See if you can join NCT07213830 on ClinicalTrials.gov

18. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MDACC, Houston, Texas

    Locations

    25 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov

19. SW-682 in Advanced Solid Tumors

    This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    U.T. MD Anderson Cancer Center, Houston, Texas

    Locations

    8 in total

    Run by

    SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

    See if you can join NCT06251310 on ClinicalTrials.gov

20. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either me…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    76 in total

    Run by

    BioNTech SE

    See if you can join NCT07070232 on ClinicalTrials.gov

21. Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

    The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    #1001, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Locations

    26 in total

    Run by

    Debiopharm International SA

    See if you can join NCT04855656 on ClinicalTrials.gov

22. Study of APR-1051 in Patients With Advanced Solid Tumors

    The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center (MDACC), Houston, Texas

    Locations

    5 in total

    Run by

    Aprea Therapeutics

    See if you can join NCT06260514 on ClinicalTrials.gov

23. Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

    BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    OncoC4, Inc.

    See if you can join NCT06635785 on ClinicalTrials.gov

24. An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    31 in total

    Run by

    BeOne Medicines

    See if you can join NCT07222267 on ClinicalTrials.gov

25. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

    This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Texas M.D. Anderson Cancer Center, Houston, Texas

    Locations

    36 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT05875168 on ClinicalTrials.gov